218 related articles for article (PubMed ID: 31570470)
1. The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients.
Georgakopoulos P; Kyriakidis M; Perpinia A; Karavidas A; Zimeras S; Mamalis N; Kouvela M; Charpidou A
Anticancer Res; 2019 Oct; 39(10):5703-5707. PubMed ID: 31570470
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up.
Georgakopoulos P; Roussou P; Matsakas E; Karavidas A; Anagnostopoulos N; Marinakis T; Galanopoulos A; Georgiakodis F; Zimeras S; Kyriakidis M; Ahimastos A
Am J Hematol; 2010 Nov; 85(11):894-6. PubMed ID: 20872550
[TBL] [Abstract][Full Text] [Related]
3. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
5. Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT).
Maier RH; Plummer C; Kasim AS; Akhter N; Ogundimu E; Maddox J; Graham J; Stewart M; Wardley A; Haney S; Vahabi S; Oxenham H; Humphreys A; Cresti N; Verrill M; Graham R; Chang L; Hancock HC; Austin D
BMJ Open; 2022 Dec; 12(12):e066252. PubMed ID: 36585130
[TBL] [Abstract][Full Text] [Related]
6. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
Lipshultz SE; Lipsitz SR; Sallan SE; Simbre VC; Shaikh SL; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2002 Dec; 20(23):4517-22. PubMed ID: 12454107
[TBL] [Abstract][Full Text] [Related]
7. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
8. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
9. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
[TBL] [Abstract][Full Text] [Related]
10. Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma.
Farina K; Kalac M; Kim S
J Oncol Pharm Pract; 2021 Jun; 27(4):1011-1015. PubMed ID: 32869692
[TBL] [Abstract][Full Text] [Related]
11. What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?
Mercurio V; Cuomo A; Della Pepa R; Ciervo D; Cella L; Pirozzi F; Parrella P; Campi G; Franco R; Varricchi G; Abete P; Marone G; Petretta M; Bonaduce D; Pacelli R; Picardi M; Tocchetti CG
Antioxid Redox Signal; 2019 Nov; 31(15):1166-1174. PubMed ID: 31436110
[TBL] [Abstract][Full Text] [Related]
12. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients.
Laursen AH; Elming MB; Ripa RS; Hasbak P; Kjær A; Køber L; Marott JL; Thune JJ; Hutchings M
J Nucl Cardiol; 2020 Oct; 27(5):1698-1707. PubMed ID: 30298372
[TBL] [Abstract][Full Text] [Related]
13. The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review.
Conway A; McCarthy AL; Lawrence P; Clark RA
BMC Cancer; 2015 May; 15():366. PubMed ID: 25948399
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.
Cardinale D; Ciceri F; Latini R; Franzosi MG; Sandri MT; Civelli M; Cucchi G; Menatti E; Mangiavacchi M; Cavina R; Barbieri E; Gori S; Colombo A; Curigliano G; Salvatici M; Rizzo A; Ghisoni F; Bianchi A; Falci C; Aquilina M; Rocca A; Monopoli A; Milandri C; Rossetti G; Bregni M; Sicuro M; Malossi A; Nassiacos D; Verusio C; Giordano M; Staszewsky L; Barlera S; Nicolis EB; Magnoli M; Masson S; Cipolla CM;
Eur J Cancer; 2018 May; 94():126-137. PubMed ID: 29567630
[TBL] [Abstract][Full Text] [Related]
16. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
[TBL] [Abstract][Full Text] [Related]
19. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.
Koleini N; Kardami E
Oncotarget; 2017 Jul; 8(28):46663-46680. PubMed ID: 28445146
[TBL] [Abstract][Full Text] [Related]
20. Rac1-mediated cardiac damage causes diastolic dysfunction in a mouse model of subacute doxorubicin-induced cardiotoxicity.
Ohlig J; Henninger C; Zander S; Merx M; Kelm M; Fritz G
Arch Toxicol; 2018 Jan; 92(1):441-453. PubMed ID: 28710503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
